Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis

Abstract Background The diagnostic utility of cardiovascular magnetic resonance (CMR) is limited during the early stages of myocarditis. This study examined whether ferumoxytol-enhanced CMR (FE-CMR) could detect an earlier stage of acute myocarditis compared to gadolinium-enhanced CMR. Methods Lewis...

Full description

Bibliographic Details
Published in:Journal of Cardiovascular Magnetic Resonance
Main Authors: Yuko Tada, Atsushi Tachibana, Shahriar Heidary, Phillip C. Yang, Michael V. McConnell, Rajesh Dash
Format: Article
Language:English
Published: Elsevier 2019-12-01
Subjects:
Online Access:https://doi.org/10.1186/s12968-019-0587-7
_version_ 1850296356123443200
author Yuko Tada
Atsushi Tachibana
Shahriar Heidary
Phillip C. Yang
Michael V. McConnell
Rajesh Dash
author_facet Yuko Tada
Atsushi Tachibana
Shahriar Heidary
Phillip C. Yang
Michael V. McConnell
Rajesh Dash
author_sort Yuko Tada
collection DOAJ
container_title Journal of Cardiovascular Magnetic Resonance
description Abstract Background The diagnostic utility of cardiovascular magnetic resonance (CMR) is limited during the early stages of myocarditis. This study examined whether ferumoxytol-enhanced CMR (FE-CMR) could detect an earlier stage of acute myocarditis compared to gadolinium-enhanced CMR. Methods Lewis rats were induced to develop autoimmune myocarditis. CMR (3 T, GE Signa) was performed at the early- (day 14, n = 7) and the peak-phase (day 21, n = 8) of myocardial inflammation. FE-CMR was evaluated as % myocardial dephasing signal loss on gradient echo images at 6 and 24 h (6 h- & 24 h-FE-CMR) following the administration of ferumoxytol (300μmolFe/kg). Pre- and post-contrast T2* mapping was also performed. Early (EGE) and late (LGE) gadolinium enhancement was obtained after the administration of gadolinium-DTPA (0.5 mmol/kg) on day 14 and 21. Healthy rats were used as control (n = 6). Results Left ventricular ejection fraction (LVEF) was preserved at day 14 with inflammatory cells but no fibrosis seen on histology. EGE and LGE at day 14 both showed limited myocardial enhancement (EGE: 11.7 ± 15.5%; LGE: 8.7 ± 8.7%; both p = ns vs. controls). In contrast, 6 h-FE-CMR detected extensive myocardial signal loss (33.2 ± 15.0%, p = 0.02 vs. EGE and p < 0.01 vs. LGE). At day 21, LVEF became significantly decreased (47.4 ± 16.4% vs control: 66.2 ± 6.1%, p < 0.01) with now extensive myocardial involvement detected on EGE, LGE, and 6 h-FE-CMR (41.6 ± 18.2% of LV). T2* mapping also detected myocardial uptake of ferumoxytol both at day 14 (6 h R2* = 299 ± 112 s− 1vs control: 125 ± 26 s− 1, p < 0.01) and day 21 (564 ± 562 s− 1, p < 0.01 vs control). Notably, the myocardium at peak-phase myocarditis also showed significantly higher pre-contrast T2* (27 ± 5 ms vs control: 16 ± 1 ms, p < 0.001), and the extent of myocardial necrosis had a strong positive correlation with T2* (r = 0.86, p < 0.001). Conclusions FE-CMR acquired at 6 h enhance detection of early stages of myocarditis before development of necrosis or fibrosis, which could potentially enable appropriate therapeutic intervention.
format Article
id doaj-art-ec0ddff97fec4e61b502aedb6044d6b3
institution Directory of Open Access Journals
issn 1532-429X
language English
publishDate 2019-12-01
publisher Elsevier
record_format Article
spelling doaj-art-ec0ddff97fec4e61b502aedb6044d6b32025-08-19T23:33:01ZengElsevierJournal of Cardiovascular Magnetic Resonance1532-429X2019-12-0121111110.1186/s12968-019-0587-7Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditisYuko Tada0Atsushi Tachibana1Shahriar Heidary2Phillip C. Yang3Michael V. McConnell4Rajesh Dash5Department of Medicine (Cardiovascular Medicine), Stanford University School of MedicineDepartment of Medicine (Cardiovascular Medicine), Stanford University School of MedicineDepartment of Medicine (Cardiovascular Medicine), Stanford University School of MedicineDepartment of Medicine (Cardiovascular Medicine), Stanford University School of MedicineDepartment of Medicine (Cardiovascular Medicine), Stanford University School of MedicineDepartment of Medicine (Cardiovascular Medicine), Stanford University School of MedicineAbstract Background The diagnostic utility of cardiovascular magnetic resonance (CMR) is limited during the early stages of myocarditis. This study examined whether ferumoxytol-enhanced CMR (FE-CMR) could detect an earlier stage of acute myocarditis compared to gadolinium-enhanced CMR. Methods Lewis rats were induced to develop autoimmune myocarditis. CMR (3 T, GE Signa) was performed at the early- (day 14, n = 7) and the peak-phase (day 21, n = 8) of myocardial inflammation. FE-CMR was evaluated as % myocardial dephasing signal loss on gradient echo images at 6 and 24 h (6 h- & 24 h-FE-CMR) following the administration of ferumoxytol (300μmolFe/kg). Pre- and post-contrast T2* mapping was also performed. Early (EGE) and late (LGE) gadolinium enhancement was obtained after the administration of gadolinium-DTPA (0.5 mmol/kg) on day 14 and 21. Healthy rats were used as control (n = 6). Results Left ventricular ejection fraction (LVEF) was preserved at day 14 with inflammatory cells but no fibrosis seen on histology. EGE and LGE at day 14 both showed limited myocardial enhancement (EGE: 11.7 ± 15.5%; LGE: 8.7 ± 8.7%; both p = ns vs. controls). In contrast, 6 h-FE-CMR detected extensive myocardial signal loss (33.2 ± 15.0%, p = 0.02 vs. EGE and p < 0.01 vs. LGE). At day 21, LVEF became significantly decreased (47.4 ± 16.4% vs control: 66.2 ± 6.1%, p < 0.01) with now extensive myocardial involvement detected on EGE, LGE, and 6 h-FE-CMR (41.6 ± 18.2% of LV). T2* mapping also detected myocardial uptake of ferumoxytol both at day 14 (6 h R2* = 299 ± 112 s− 1vs control: 125 ± 26 s− 1, p < 0.01) and day 21 (564 ± 562 s− 1, p < 0.01 vs control). Notably, the myocardium at peak-phase myocarditis also showed significantly higher pre-contrast T2* (27 ± 5 ms vs control: 16 ± 1 ms, p < 0.001), and the extent of myocardial necrosis had a strong positive correlation with T2* (r = 0.86, p < 0.001). Conclusions FE-CMR acquired at 6 h enhance detection of early stages of myocarditis before development of necrosis or fibrosis, which could potentially enable appropriate therapeutic intervention.https://doi.org/10.1186/s12968-019-0587-7FerumoxytolCMRMRIMyocarditisT2* map
spellingShingle Yuko Tada
Atsushi Tachibana
Shahriar Heidary
Phillip C. Yang
Michael V. McConnell
Rajesh Dash
Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis
Ferumoxytol
CMR
MRI
Myocarditis
T2* map
title Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis
title_full Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis
title_fullStr Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis
title_full_unstemmed Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis
title_short Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis
title_sort ferumoxytol enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis
topic Ferumoxytol
CMR
MRI
Myocarditis
T2* map
url https://doi.org/10.1186/s12968-019-0587-7
work_keys_str_mv AT yukotada ferumoxytolenhancedcardiovascularmagneticresonancedetectionofearlystageacutemyocarditis
AT atsushitachibana ferumoxytolenhancedcardiovascularmagneticresonancedetectionofearlystageacutemyocarditis
AT shahriarheidary ferumoxytolenhancedcardiovascularmagneticresonancedetectionofearlystageacutemyocarditis
AT phillipcyang ferumoxytolenhancedcardiovascularmagneticresonancedetectionofearlystageacutemyocarditis
AT michaelvmcconnell ferumoxytolenhancedcardiovascularmagneticresonancedetectionofearlystageacutemyocarditis
AT rajeshdash ferumoxytolenhancedcardiovascularmagneticresonancedetectionofearlystageacutemyocarditis